Theravance Biopharma (TBPH) FCF Margin (2013 - 2026)
Theravance Biopharma's (TBPH) quarterly FCF Margin came in at 414.03% in Q1 2026, up 13434.0% year-on-year from N/an in Q1 2025, and up 3229.15% on a QoQ basis from 13.23% in Q4 2025.
Theravance Biopharma (TBPH) FCF Margin (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of FCF Margin data on file, last reported at 414.03% in Q1 2026.
- On a quarterly basis, FCF Margin rose 13434.0% year-over-year to 414.03% in Q1 2026; TTM through Mar 2026 was 244.84%, a 19537.0% increase from a year earlier, with the FY2025 full-year figure at 3179.99%, up 319842.0% from the prior year.
- FCF Margin for Q1 2026 stood at 414.03%, up from 13.23% in the prior quarter.
- Over the last five years, FCF Margin for TBPH reached as high as 794.33% in Q2 2025 and fell as low as 199.45% in Q1 2022.
- Historically, FCF Margin has averaged 60.91% across 5 years, with a median of 15.98% in 2023.
- Across the five-year window, FCF Margin plunged 38176 bps in 2023 and surged 82555 bps in 2025, its largest moves.
- Year by year, FCF Margin stood at 373.04% in 2022, then plunged by 102 bps to 8.72% in 2023, then surged by 33 bps to 5.82% in 2024, then plunged by 127 bps to 13.23% in 2025, then soared by 3229 bps to 414.03% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 414.03% in Q1 2026, 13.23% in Q4 2025, and 32.56% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Theravance Biopharma | 864.56 Mn | 469.90 Mn | - | 414.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 414.03% |
| Dec 31, 2025 | -13.23% |
| Sep 30, 2025 | -32.56% |
| Jun 30, 2025 | 794.33% |
| Mar 31, 2025 | 279.69% |
| Dec 31, 2024 | -5.82% |
| Sep 30, 2024 | -30.89% |
| Jun 30, 2024 | -31.22% |
| Mar 31, 2024 | -7.67% |
| Dec 31, 2023 | -8.72% |
| Sep 30, 2023 | -15.98% |
| Jun 30, 2023 | -96.65% |
| Mar 31, 2023 | -116.72% |
| Dec 31, 2022 | 373.04% |
| Sep 30, 2022 | -132.37% |
| Jun 30, 2022 | -134.33% |
| Mar 31, 2022 | -199.45% |
| Dec 31, 2021 | -286.89% |
| Sep 30, 2021 | -352.32% |
| Jun 30, 2021 | -389.26% |